The Medicines and Healthcare products Regulatory Agency (MHRA) in London is investigating the hospitalization of six men who took part in a Phase I trial of TGN1412, an immunomodulatory humanized agonistic anti-CD28 monoclonal antibody designed to treat chronic inflammatory conditions and leukemia. (BioWorld Today) Read More
